What the Research Says
Nootropic supplements encompass a range of compounds with distinct mechanisms and varying levels of clinical evidence. Bacopa monnieri and phosphatidylserine each have clinical evidence from multiple studies.
Kongkeaw et al. (2014) conducted a meta-analysis of 9 RCTs evaluating bacopa monnieri in 518 subjects, concluding that standardized bacopa extract significantly improved attention, cognitive processing speed, and working memory. The meta-analysis noted that benefits required a minimum of 12 weeks of supplementation, consistent with bacopa's mechanism of action through bacoside-mediated synaptic plasticity.
Glade & Smith (2015) reviewed the evidence for phosphatidylserine, documenting its role in supporting cognitive function across aging populations. Evidence that phosphatidylserine may reduce the risk of dementia or cognitive dysfunction in the elderly remains very limited and preliminary. Effective doses range from 100-300mg daily.
Mori et al. (2009) provided the foundational clinical evidence for lion's mane mushroom, demonstrating significant cognitive improvements in elderly subjects with mild cognitive impairment over a 16-week double-blind trial. The benefits were attributed to hericenone-stimulated nerve growth factor synthesis.
Nobre et al. (2008) investigated L-theanine's neurophysiological effects, showing that even modest doses (50mg) increased alpha brain wave activity — the neural signature of relaxed alertness — within 45 minutes of ingestion. This finding supports L-theanine's use as a focus-enhancing nootropic, particularly when combined with caffeine.
Collectively, the evidence supports a targeted approach to nootropic supplementation: selecting specific compounds at clinically validated doses rather than relying on proprietary blends with undisclosed ingredient amounts.
